BACKGROUND: Overexpression of mucin-5AC (MUC5AC) makes it a targetable biomarker in pancreatic cancer. The present study evaluated tumor targeting with a MUC5AC antibody conjugated to a near-infrared dye in a patient-derived orthotopic xenograft (PDOX) mouse model. MATERIALS AND METHODS: MUC5AC monoclonal antibody was conjugated to the near-infrared dye IRDye800CW to synthesize MUC5AC-IR800. PDOX models were established by implanting a high-MUC5AC-expressing patient-derived pancreatic tumor on the pancreas of nude mice. After 4 weeks of PDOX tumor growth, mice were imaged after receiving MUC5AC-IR800 (75 μg) intravenously. RESULTS: In the PDOX models, MUC5AC-IR800 selectively and brightly targeted the pancreatic tumor (tumor to background ratio: 2.46±0.465). CONCLUSION: MUC5AC-IR800 provides distinct visualization of pancreatic tumors. MUC5AC-IR800 may be used clinically in the future to improve pancreatic cancer resection. This novel fluorescent probe is also promising for targeting of pre-malignant pancreatic lesions with subsequent resection under fluorescence guidance.
BACKGROUND: Overexpression of mucin-5AC (MUC5AC) makes it a targetable biomarker in pancreatic cancer. The present study evaluated tumor targeting with a MUC5AC antibody conjugated to a near-infrared dye in a patient-derived orthotopic xenograft (PDOX) mouse model. MATERIALS AND METHODS: MUC5AC monoclonal antibody was conjugated to the near-infrared dye IRDye800CW to synthesize MUC5AC-IR800. PDOX models were established by implanting a high-MUC5AC-expressing patient-derived pancreatic tumor on the pancreas of nude mice. After 4 weeks of PDOX tumor growth, mice were imaged after receiving MUC5AC-IR800 (75 μg) intravenously. RESULTS: In the PDOX models, MUC5AC-IR800 selectively and brightly targeted the pancreatic tumor (tumor to background ratio: 2.46±0.465). CONCLUSION: MUC5AC-IR800 provides distinct visualization of pancreatic tumors. MUC5AC-IR800 may be used clinically in the future to improve pancreatic cancer resection. This novel fluorescent probe is also promising for targeting of pre-malignant pancreatic lesions with subsequent resection under fluorescence guidance.
Authors: Hop S Tran Cao; Sharmeela Kaushal; Cristina A Metildi; Rhiana S Menen; Claudia Lee; Cynthia S Snyder; Karen Messer; Minya Pu; George A Luiken; Mark A Talamini; Robert M Hoffman; Michael Bouvet Journal: Hepatogastroenterology Date: 2012-09
Authors: Cristina A Metildi; Sharmeela Kaushal; Chanae R Hardamon; Cynthia S Snyder; Minya Pu; Karen S Messer; Mark A Talamini; Robert M Hoffman; Michael Bouvet Journal: J Am Coll Surg Date: 2012-05-24 Impact factor: 6.113
Authors: Bettina M Rau; Katharina Moritz; Sarah Schuschan; Guido Alsfasser; Friedrich Prall; Ernst Klar Journal: Surgery Date: 2012-07-03 Impact factor: 3.982
Authors: Grace E Kim; Han-Ik Bae; Hee-Ug Park; Shih-Fan Kuan; Suzanne C Crawley; Jenny J L Ho; Young S Kim Journal: Gastroenterology Date: 2002-10 Impact factor: 22.682
Authors: Hannah M Hollandsworth; Siamak Amirfakhri; Filemoni Filemoni; Verena Schmitt; Gunther Wennemuth; Alexej Schmidt; Robert M Hoffman; Bernhard B Singer; Michael Bouvet Journal: Oncotarget Date: 2020-01-28
Authors: Eric Pion; Julia Karnosky; Sofie Boscheck; Benedikt J Wagner; Katharina M Schmidt; Stefan M Brunner; Hans J Schlitt; Thiha Aung; Christina Hackl; Silke Haerteis Journal: Cancers (Basel) Date: 2022-07-31 Impact factor: 6.575